Skip to main navigation menu Skip to main content Skip to site footer

Articles

Año 6 No. 16 Enero - Abril 2020

Genetic doping. To whom does success belong?

DOI
https://doi.org/10.32399/icuap.rdic.2448-5829.2020.16.274
Submitted
November 12, 2020
Published
January 15, 2020

Abstract

Gene therapy is a technique that allows the treatment of diseases by replacing or inactivating genes that cause diseases or introducing new genes to fight them. With its development you can not only treat diseases but also enhance human performance, opening the possibility for athletes to use gene therapy to improve their performance. Genetic doping is defined as the non-therapeutic use of genes, genetic elements or cells that have the ability to increase athletic performance. With current technology, it is not possible to detect this type of doping and since it causes a permanent alteration, which could define the winner in competition and affect the health of athletes in the long term, it is one of the methods prohibited by the World Anti-Doping Agency. In addition, the following questions arise with its use: To whom does the triumph of an athlete who used genetic doping really belong? To the athlete or the interdisciplinary workgroup that made the application of gene therapy possible in him?

References

  1. Crystal RG1. Transfer of genes to humans: early lessons and obstacles to success. Science. 270(5235):404-10 (1995).
  2. Binley K., Askham Z., Iqball S., Spearman H., Martin L., de Alwis M., Thrasher A.J., Ali R.R., Maxwell P.H., Kingsman S., Naylor S. Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood. 100(7):2406-13 (2002).
  3. Brzeziańska E., Domańska D., and Jegier A. Gene doping in sport – Perspectives and risks. Biol Sport. 31(4): 251–259 (2014).
  4. Cantelmo R.A., Da Silva A.P., Mendes-Junior C.T., Dorta D.J. Gene doping: Present and future. Eur J Sport Sci.1:1-9 (2019).
  5. Colella P., Ronzitti G., Mingozzi F. Emerging Issues in AAV-Mediated In Vivo Gene Therapy. Mol Ther Methods Clin Dev.8:87-104 (2017).
  6. Goñi, Félix The basic structure and dynamics of cell membranes: An update of the Singer–Nicolson model. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1838(6):1467-1476 (2014).
  7. Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother. 40(5):302-9 (2013).
  8. Mir L.M. (2014) Electroporation-Based Gene Therapy: Recent Evolution in the Mechanism Description and Technology Developments. Biology (Methods and Protocols). Methods in molecular biology. 1121:3-23 (2014).
  9. Pillai AA, Babiker HM. Polycythemia. [Updated 2019 May 5]. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019. Consultado de https://www.ncbi.nlm.nih.gov/books/NBK526081/ el 04 de diciembre de 2019.
  10. Kumar S.R., Markusic D.M., Biswas M., High K.A., and Herzog R.W. Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev. 3:16034 (2016).
  11. Unal M., Ozer Unal D. Gene doping in sports. Sports Med. 34(6):357-62 (2004)